Hospital of St. Raphael, Yale University, New Haven, Connecticut, USA.
Perit Dial Int. 2011 May-Jun;31(3):279-86. doi: 10.3747/pdi.2010.00196.
Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis (PD). The reported incidence varies between 0.5% and 4.4% and increases with length of time on PD. Very few data are available on the epidemiology of EPS in the United States. The aim of the present study was assess the incidence of EPS in a single center in New Haven, Connecticut. In a retrospective analysis of all patients maintained on PD for 5 or more years, clinical symptoms were documented, abdominal computed tomography (CT) findings were reviewed, and surgical and pathology findings were noted. Patients were tracked whether they remained on PD, transferred to hemodialysis (HD), underwent transplantation, or died. Among the 76 patients that met the inclusion criteria (mean dialysis duration: 81.5 ± 22 months), 14 (18%) developed clinical symptoms (persisting for 3 or more months) suggestive of EPS. Abdominal CT imaging was done in 38 patients; 25 had radiologic features consistent with EPS. At laparotomy, 6 of 7 patients had gross findings consistent with EPS. Eleven patients met the 2000 criteria of the International Society for Peritoneal Dialysis for a diagnosis of EPS; they had clinical features, plus either radiologic or histopathologic confirmation. In 3 patients with clinical symptoms, the radiologic or surgical findings did not support a diagnosis of EPS. Of the 11 patients meeting the EPS criteria, 1 remains on PD and is doing well, 2 were transferred to HD and are doing well, 2 died as a result of EPS complications, and 6 died of other causes. The present study suggests that, in patients maintained on PD for 5 or more years at our center, the incidence of EPS is 14%. Those findings suggest that EPS may be underrecognized in the United States and that a high index of suspicion is warranted in patients maintained on PD for 5 or more years.
包裹性腹膜硬化症(EPS)是长期腹膜透析(PD)的严重并发症。报告的发病率在 0.5%至 4.4%之间,随着 PD 时间的延长而增加。关于美国 EPS 的流行病学数据非常有限。本研究旨在评估康涅狄格州纽黑文市一家单中心的 EPS 发病率。对所有接受 PD 治疗 5 年或以上的患者进行回顾性分析,记录临床症状,回顾腹部计算机断层扫描(CT)结果,并注意手术和病理结果。跟踪患者是继续接受 PD 治疗、转血液透析(HD)治疗、接受移植还是死亡。在符合纳入标准的 76 名患者中(平均透析时间:81.5 ± 22 个月),14 名(18%)出现了持续 3 个月或以上的临床症状(提示 EPS)。对 38 名患者进行了腹部 CT 成像;25 名患者的影像学表现符合 EPS。在剖腹手术中,7 名患者中有 6 名的大体表现符合 EPS。11 名患者符合国际腹膜透析学会 2000 年 EPS 诊断标准;他们有临床特征,加上影像学或组织病理学证实。在 3 名有临床症状的患者中,影像学或手术结果不支持 EPS 诊断。在符合 EPS 标准的 11 名患者中,1 名仍在接受 PD 治疗,情况良好,2 名转 HD 治疗,情况良好,2 名因 EPS 并发症死亡,6 名因其他原因死亡。本研究表明,在我们中心接受 PD 治疗 5 年或以上的患者中,EPS 的发病率为 14%。这些发现表明,在美国,EPS 可能被低估,对于接受 PD 治疗 5 年或以上的患者,应保持高度怀疑。